Brinson Patrick Securities Develops Life Sciences Advisory Board
Brinson Patrick expands focus on life sciences companies by
appointing Gregory Hanson and Jack Florio to join Vivian Liu as advisor
NEW YORK, Oct. 25, 2011 – Brinson Patrick Securities, a boutique investment bank that focuses specifically on at-the-market (ATM) offerings, today announced that Gregory Hanson and Jack Florio have been appointed as advisors and will join its current advisor, Vivian Liu, in the development of a life
sciences advisory board. The advisory board will provide Brinson Patrick’s management team with additional perspective and understanding of the financial needs of the emerging life sciences community and will help Brinson Patrick to expand its offerings in this important industry sector. All three have
many years of experience helping life sciences companies raise capital.
“The operational experience of our newly developed life sciences advisory board will complement our focus and commitment to the continued expansion of our ATM offering for the life sciences industry,” commented Todd Wyche, founder and managing director of Brinson Patrick. “Vivian, Greg and Jack have held significant operational roles with various life sciences companies, and all three have a deep understanding of the benefit of ATMs. Their advice will be invaluable in helping us to offer an important financing option to life sciences CFOs.”
Mr. Hanson is currently managing director of First Cornerstone, a board, management and financial advisory service for both private and public companies located in San Diego. He has over 35 years of experience in both the public and private sectors and currently serves as an advisory board
member and acting CFO of a private company. Before being employed at his current position, Mr. Hanson has served as the CFO of Avanir Pharmaceuticals, Adventrix Pharmaceuticals, XXsys Technologies and Onsite Energy.
Prior to joining Brinson Patrick’s life sciences advisory board, Mr. Florio served as Brinson Patrick’s senior vice president in its San Diego office. Before joining
Brinson Patrick in 2008, he spent eight years in the life sciences and biotech industry in various management roles and as an angel investor. He has worked in the life sciences industry since 1973 with a 30 year career with Eli Lilly and
Ms. Liu has served as advisor to Brinson Patrick since February of this year. She is currently president and chief executive officer of FastTrack Pharmaceuticals. Prior to that, she served as president, chief executive officer and chairman of the board of NexMed.
Brinson Patrick has recently announced the increased use of ATM offerings by life sciences companies compared to previous years. ATM offerings provide an efficient means of raising equity capital over time, making them ideal for raising general working capital, funding specific projects, funding research and development and paying off debt. ATM offerings provide flexibility, efficiency, control, discretion and just-in-time capital with minimal dilution of stock when
managed by an experienced ATM underwriter.
With an ATM, an exchange-listed company incrementally sells newly issued shares into the trading market through a designated broker-dealer at prevailing
market prices, rather than via a traditional underwritten offering of a fixed number of shares at a fixed price all at once. ATMs enable publicly-traded companies to tap into the existing secondary market for shares on an asneeded basis.
About Brinson Patrick Securities Corporation
Brinson Patrick Securities Corporation is a boutique investment bank that employs a single financing tool − DOCS® (Dynamic Offering of Common Stock) at-the-market (ATM) financing facility − to raise the capital for clients as they need it.
The DOCS® ATM is a low-profile equity offering appropriate for publicly traded companies across multiple industries and market capitalizations. It has been successfully utilized by companies in the energy, life science, technology, real estate, financial services and hospitality industries with market capitalizations that range from $50 million to over $1 billion.
For more information, visit http://www.brinsonpatrick.com.
Brinson Patrick is a FINRA member broker-dealer.
Robert Flamm, Ph.D.
and David Schull
EDITOR’S NOTE: Visit www.brinsonpatrick.com/news/media-kit to access Brinson Patrick’s fact sheet.